Get started
Marker Therapeutics, Inc.Marker Therapeutics, Inc.Marker Therapeutics, Inc.

Marker Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

MRKR trade ideas

RiskMastery's Breakout Stocks - MRKR EditionWelcome to RiskMastery's Breakout Stocks - Stocks with breakout potential. In this edition, we'll be looking at NASDAQ:MRKR ... I believe this code is at a point of potential volatility. If price can hold above $4.67 ... Bullish potential may be unlocked. My key upside targets include: - $6.21 (Conservative) - $7.59 (Medium) - $9.12 (Aggressive) If however price falls below $3.41 ... Bearish risk potential may be unlocked. (My key risk targets - C, M,& A - are as noted on the chart) Enjoy, and I look forward to being of further service into the future. If you'd like to connect, feel free to reach out and comment below. Mr RM | Risk Mastery Disclaimer: This post is intended for educational purposes only - Publicly available RiskMastery information & content is not intended to be financial advice in any shape or form. Please do your own research and seek advice from a licensed professional before acting on any of the information contained within this post. This post is not a solicitation or recommendation to buy, sell or hold any positions in any financial instrument. All demonstrated trades are merely incidental to the educational training RiskMastery aims to provide. You are solely responsible for your own investment and trading decisions, of which should be made only according to your own opinion, knowledge and experience. You should not rely on any of the information contained on this site or contained in any RiskMastery material on any website or platform. You assume the sole risk of any trade or investment you elect to make. RiskMastery and affiliates shall not be liable to you for any monetary losses or any other damages incurred directly or indirectly, from your use, reliance or reference of RiskMastery materials, content and educational information. Thank you for your understanding and cooperation - We look forward to working with you into the future to navigate the fine line of trading and investment success.
NASDAQ:MRKRLong
by Bullfinder-official
MRKR (Marker Therapeutics, Inc): Something with huge Risk:RewardHello folks MRKR (Marker Therapeutics, Inc) still sleeping but its worth to thinking about. Why? MARKER THERAPEUTICS is a clinical-stage immuno-oncology c NASDAQ:MRKR ompany, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Company news are incredibly good and forecast of stock is very bright because they find to But this symbol needs some confident from traders. Today's price is interesting for value investors. MRKR is one of the under-radar stocks. we love it! Now what? We added more to this symbol and details are below: Target 1: 5.95 USD (%160 Reward) Target 2: 7.90 USD (%250 Reward) Stop Loss: 2.00 USD (%10 Risk) Entry Type: Buy Limit Entry Point: 2.25 Risk Reward Ratio: 1:16 & 1:24 Stay safe and refer us to your friends and follow us for new ideas. More data for who like to read: "We are pleased with the results of the safety lead-in portion of the trial, in which all six patients met the safety endpoints following infusion of our MultiTAA-specific T cell therapy," said Mythili Koneru, M.D., Ph.D., Chief Medical Officer of Marker Therapeutics. "We are currently enrolling patients in the main portion of our first Company-sponsored trial and continue to activate clinical sites across the U.S. We are looking forward to further advancing MT-401 in this disease setting. Despite recent advances in how hematological malignancies are treated, patients remain in urgent need of new therapeutic options." About Marker's Phase 2 AML Post-Transplant Study The multicenter Phase 2 AML study is evaluating the clinical efficacy of MT-401 in patients with AML following an allogeneic stem-cell transplant in both the adjuvant and active disease setting. In the adjuvant setting, approximately 120 patients will be randomized 1:1 to either MT-401 at 90 days post-transplant versus standard-of-care observation, while approximately 40 patients with active disease will receive MT-401 as part of the single-arm group. The primary objectives of the trial are to evaluate relapse-free survival in the adjuvant group and determine the complete remission rate and duration of complete remission in active disease patients. Additional objectives include, for the adjuvant group, overall survival and graft-versus-host disease relapse-free survival while additional objectives for the active disease group include overall response rate, duration of response, progression-free survival and overall survival. In April 2020, the FDA granted Orphan Drug designation to MT-401 for the treatment of patients with AML following allogeneic stem cell transplant. Forward-Looking Statements This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials, including the Phase 2 trial of MT-401; and the overall market opportunity for our product candidates. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at sec gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
NASDAQ:MRKRLong
by StockAndMoreCom
MRKR: Bullish Flag (48%)Bullish Flag (48%) Pros: Volume during post formation Descending volume during Flag formation Golden cross in blue PPS above 200MA RS above 0 R/R ratio above 3 ATR ascending Cons: 200MA flat 250RSI below 50 PPS below 50MA RS Flat descending Target: PT = 3.50$ Help how ever you can to keep this alive. Thank you to those who have donated Coins! Always do your own due dilligence. This is not financial advice Stay Humble, have fun, make money! Education: www.dailyfx.com
NASDAQ:MRKRLong
by LeLaf
MRKR (NASDAQ) - Gap should be closedGreetings Humbled, we would like to thanks for your support who has already liked, commented and followed us. Your support, strengthens us, to help in analyzing the market. If you have any questions, feel free to send us message (inbox). Pra Trading : - Please care for Money Management - Have a good psychology - Do not be hurry to open position and do not do nothing if u see opportunity - Evaluate and upgrade your trading plan Execution Strategy : - Know what you want to buy, see the Fundamental - Decide that you are on investing or speculating - Consider what your strategy based on Investing/Speculating - Make Road Map Of Your Trading Plan - Decide a. Entry strategy b. Cut loss c. Target of Profit Post Trading : a. Do not be sad if you loss or do not be very happy if you win b. Just become a normal without emotion, Do not put emotion into your trading c. Evaluate your trading d. Keep on Learning e. Be Humble Idea : MRKR (NASDAQ) - Gap should be closed
NASDAQ:MRKR
by MultiAssetX
Is This Volume Any Indicator Of A New Trend?MRKR has been a sleeper all year. No major high-volume days and nothing really to write home about. But it managed to pull off a bigger move earlier on. Now that the gap has filled from the drop a few weeks ago & they secured funds, what will this mean for the company's next steps? "An onslaught of Form 4s showed hand fulls of investors and insiders participating in the recent offering. The company raised the money to fund its Phase 2 trial of MT-401 in acute myeloid leukemia. Marker also plans to develop MultiTAA therapies into clinical trials in other indications and conduct manufacturing activities, among other things. In addition to this, analysts have also weighed in recently. Cantor Fitzgerald initiated coverage on Marker this month. The firm started MRKR at Overweight and gave a price target of $6." Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:MRKR
by PennyStocks101
Stock to watch: TapImmune Inc. common stock (MRKR) - risk-tradeNASDAQ:MRKR A risky yet interesting trade: Buy/Sell Zones is in the green line, but we should consider it as a pullback - the overall downtrend + bearish momentum. I may consider Short up 0.786 Fib (where we can see another pullback) but could dip even lower. Invalidation: closing above 1.75 on higher timeframes (12H, 1D). Disclaimer: This article should not be considered as financial or investment advice. Trading digital assets involve risk and may resolve in the loss of your capital. Always be sure to understand the amount of risk involved and do your research before taking any trading/investment steps.
NASDAQ:MRKRShort
by randomname11
Potential Reversal Marker TherapeuticsMRKR Entered MRKR at $4.01 on Friday (11/1/19) and am monitoring for a sustained trend reversal. Watching for SP to bounce off $4.10, or if that does not hold, $4.01. If it does not reverse here I think it'll consolidate between $3.83 and $4.32. A reversal would coincide with a run-up into Q3 earnings which should be sometime this month and phase 2 data in Ovarian Cancer expected this quarter. Closing over $4.32 would be a good confirmation of a trend reversal. RSI and CCI on the daily support the stock is building momentum IMO.
NASDAQ:MRKRLong
by MS_Money_Moves
MARKER THERAPEUTICS INC - NASDAQ: $MRKR ConsolidatesAfter recapturing its 200 DMA a week ago on meaningful volume, the shares of MARKER THERAPEUTICS INC - NASDAQ;MRKR have found themselves consolidating the recent move in a constructive and orderly manner as is evidenced in the Daily chart above. With the stock now trading above all of its important moving averages 20/50/200 DMA's, the technical posture is favorable for MRKR . In addition, there are potential catalysts for the stock forthcoming in the weeks ahead, in particular, Marker Therapeutics is to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma on July 20, 2019. finance.yahoo.com Thus, moving forward, both investors/traders may want to continue to monitor the action closely and should MRKR be capable of going topside of the $8.15 figure at any point in the days ahead, we suspect that the stock may just have eyes for the $9 - $10 zone once the present consolidation runs its course.
NASDAQ:MRKR
by OptionsGains